阿霉素
三阴性乳腺癌
多重耐药
癌症
癌症研究
脂质体
乳腺癌
材料科学
药物输送
纳米技术
药理学
化疗
抗药性
医学
生物
内科学
微生物学
作者
Zhou J. Deng,Stephen W. Morton,Elana Ben‐Akiva,Erik C. Dreaden,Kevin E. Shopsowitz,Paula T. Hammond
出处
期刊:ACS Nano
[American Chemical Society]
日期:2013-10-21
卷期号:7 (11): 9571-9584
被引量:510
摘要
A single nanoparticle platform has been developed through the modular and controlled layer-by-layer process to codeliver siRNA that knocks down a drug-resistance pathway in tumor cells and a chemotherapy drug to challenge a highly aggressive form of triple-negative breast cancer. Layer-by-layer films were formed on nanoparticles by alternately depositing siRNA and poly-l-arginine; a single bilayer on the nanoparticle surface could effectively load up to 3500 siRNA molecules, and the resulting LbL nanoparticles exhibit an extended serum half-life of 28 h. In animal models, one dose via intravenous administration significantly reduced the target gene expression in the tumors by almost 80%. By generating the siRNA-loaded film atop a doxorubicin-loaded liposome, we identified an effective combination therapy with siRNA targeting multidrug resistance protein 1, which significantly enhanced doxorubicin efficacy by 4 fold in vitro and led to up to an 8-fold decrease in tumor volume compared to the control treatments with no observed toxicity. The results indicate that the use of layer-by-layer films to modify a simple liposomal doxorubicin delivery construct with a synergistic siRNA can lead to significant tumor reduction in the cancers that are otherwise nonresponsive to treatment with Doxil or other common chemotherapy drugs. This approach provides a potential strategy to treat aggressive and resistant cancers, and a modular platform for a broad range of controlled multidrug therapies customizable to the cancer type in a singular nanoparticle delivery system.
科研通智能强力驱动
Strongly Powered by AbleSci AI